Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis☆☆☆★★★♢

Effects of once daily dosing with inhaled budesonide on airway hyperresponsiveness and airway inflammation following repeated low‐dose allergen challenge in atopic asthmatics

“…This study has demonstrated, that once daily dosing of inhaled budesonide 400 μg is effective in preventing allergen‐induced airway responses. Several studies have demonstrated the clinical efficacy of once daily inhaled budesonide in patients with mild to moderate persisting asthma [ 26, 38], and furthermore, in the control of nasal symptoms associated with perennial [ 39] and allergen‐induced nasal rhinitis [ 40]. The results of the present study raise the possibility that once daily treatment with low doses of budesonide may be beneficial to atopic asthmatics during seasonal allergen exposure.…”

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis

“…The baseline RTSS4 was around 7, and we considered a change in score of 3 or more as a clinically relevant improvement of symptoms because in randomized, placebo-controlled clinical trials a RTSS4 reduction of 20% to 35% is observed in the placebo group, whereas a 40% to 50% reduction in RTSS is observed in the active group. [22][23][24][25][26][27][28][29] These cutoff levels were an a priori choice. Finally, because QOL and symptoms do not assess the same dimension, RQLQ score and RTSS4 variations were combined.…”

Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care

“…In most trials, patients under placebo have a mean improvement of RQLQ around 1 point [9,23,24,[27][28][29], we therefore considered a score change of 1 point as a clinically significant change of RQLQ. The TSS6 was considered to be improved if patients had a 50% change in symptoms improvement [28][29][30][31][32][33][34]. The baseline TSS6 was close to 10 in our study and we considered an a priori change of 5 points, on a scale ranging from 0 to 18, as a clinically relevant improvement of symptoms.…”